If the filing person has previously filed a statement on Schedule 13G
to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f)
or Rule 13d-1(g), check the following box .☐
NOTE: Schedules filed in paper format
shall include a signed original and five copies of the Schedule, including all exhibits. See Rule 13d-7(b) for other parties
to whom copies are to be sent.
*The remainder of this cover
page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required on
the remainder of this cover page shall not be deemed to be “filed” for purpose of Section 18 of the Securities Exchange Act
of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions
of the Act (however, see the Notes)
|
CUSIP No.
60743F 50 8 |
SCHEDULE 13D |
Page 2 of 5 Pages |
| 1 |
NAME OF REPORTING PERSONS
Gene Salkind
|
| 2 |
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ☐
(b) ☐ |
| 3 |
SEC USE ONLY
|
| 4 |
SOURCE OF FUNDS
Not applicable. (Conversion)
|
| 5 |
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO
ITEM 2(d) or 2(e) ☐
|
| 6 |
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
|
NUMBER OF |
7 |
SOLE VOTING POWER
|
3,721,854 |
|
SHARES
BENEFICIALLY |
8 |
SHARED VOTING POWER
|
0 |
|
OWNED BY
EACH |
9 |
SOLE DISPOSITIVE POWER
|
3,721,854 |
|
REPORTING
PERSON WITH |
10 |
SHARED DISPOSITIVE POWER
|
0 |
| 11 |
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,721,854
|
| 12 |
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES /x/
Excludes 63,750 warrants issuable upon conversion of $510,000
of debt. |
| 13 |
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
40.6% (1)
|
| 14 |
TYPE OF REPORTING PERSON
IN
|
| |
|
|
|
|
| (1) |
Based upon 6,560,751 common shares outstanding prior to March 30, 2022. |
|
CUSIP No.
60743F 50 8 |
SCHEDULE 13D |
Page 3 of 5 Pages |
ITEM 1. Security and Issuer.
The securities to which this Schedule 13D relates are the common
shares, $0.0001 par value per share (“Common Shares”) of Mobiquity Technologies, Inc., a New York corporation (the “Issuer”).
The address of the executive offices of the Issuer is 35 Torrington Lane, Shoreham, NY 11766.
ITEM 2. Identity and Background.
(a) – (c) This Statement is filed by Gene Salkind. Dr. Salkind’s
address is 1165 Wrack Road, Meadowbrook, PA 19046. Dr. Salkind is a practicing neurologist in Pennsylvania.
(d) - (e) During the last
five years, Dr. Salkind has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) nor has
he been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding
was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject
to, federal or state securities laws, or finding violations with respect to such laws.
(f) Mr. Salkind is a United States citizen.
ITEM 3. Source and Amount of Funds or Other Consideration.
Dr. Salkind used his personal funds to make investments in the Issuer
over the last several years. The most recent transaction described in Item 5 is an exchange or conversion of promissory notes for common
stock and warrants.
ITEM 4. Purpose of Transaction.
Dr. Salkin is Chairman of the Board of the Issuer and a principal stockholder.
The purpose of the transaction described in Item 5 is to increase the Company’s stockholder equity by $2,052,500 in the first quarter
of 2022 to ensure compliance with NASDAQ Capital Market maintenance requirements.
Except as described above, Mr. Salkin presently has no plans or proposals
which relate to or would result in any action enumerated in subparagraphs (a) through (j) of the instructions for Item 4
of Schedule 13D.
ITEM 5. Interest in Securities of the Issuer.
(a), (b) Dr. Salkind beneficially owns 2,484,354
common shares of the Issuer and derivative securities to purchase 1,237,500 common shares for an aggregate ownership interest of 3,721,854
common shares or 40.6% of the Company’s outstanding common stock. Dr. Salkind may be deemed to be the beneficial owner with sole
voting and dispositive power of 3,721,854 shares of Common Stock, or 40.6% of the class of securities. The foregoing excludes 63,750 warrants
issuable upon conversion of notes in the principal amount of $510,000. The foregoing ownership is owned partly in Dr. Salkind’s
name, partly by Dr. Salkind and his spouse and partly in a trust in which Dr. Salkind is the trustee.
|
CUSIP No.
60743F 50 8 |
SCHEDULE 13D |
Page 4 of 5 Pages |
(c) During the last 60 days, the following issuances of the Issuer’s
Common Shares were made to Dr. Salkind:
On March 30, 2022 prior to the close of the market,
Dr. Salkind requested a board meeting to consider his offer to convert and the board approved his conversion of $2,052,500 of his convertible
secured debt at a reduced conversion price of $1.50 per share (down from $4.00 per share) for the primary purpose of adding $2,052,500
to the Issuer’s stockholders equity to insure compliance with the NASDAQ maintenance requirements for continued listing.
(d) and (e) Not applicable.
ITEM 6. Contracts, Arrangements, Understandings or Relationship
with Respect to the Securities of the Issuer.
No contracts, arrangements, understandings, or relationships (legal
or otherwise) exist between Dr. Salkind and any person with respect to any securities of the Issuer, including, but not limited to, transfer
or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits,
divisions of profits or loss, or the giving or withholding of proxies.
| Item 7. | Materials to be filed as Exhibits |
Not applicable.
SIGNATURES
After reasonable inquiry and
to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
| |
|
|
| |
|
|
|
| Dated: March 31, 2022 |
By: |
/s/ Dr. Gene Salkind |
|
| |
|
Dr. Gene Salkind |
|
| |
|
|
|